Threshold Pharmaceuticals (THLD) Surges On Positive Pancreatic Cancer Trial Data
Tweet
Share
E-mailGet Alerts THLD Hot Sheet
Join SI Premium – FREE
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) is surging over 60 percent in pre-open trading Tuesday following positive Phase 2b clinical trial results of TH-302 in pancreatic cancer.
The company said the primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). Also, the combination therapy was well tolerated with a safety profile consistent with prior studies.
The company said the primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). Also, the combination therapy was well tolerated with a safety profile consistent with prior studies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ascletis to present obesity drug combo data at EASD meeting
- FDA accepts BridgeBio NDA for encaleret to treat ADH1
- Trinity Biotech partners with Latch Medical on biosensor-guided drug delivery
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
